{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:56:11Z","timestamp":1794938171081,"version":"4.9.1"},"reference-count":35,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japanese Ministry of Health, Labour, and Welfare","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Krebs von den Lungen-6 (KL-6) levels measured at baseline have been reported as a circulating biomarker useful for the detection, evaluation of severity and assessment of risk of the progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). In this retrospective study, longitudinal changes in serum KL-6 levels over 2 years were examined in 110 patients with SSc using prospectively collected cohort data. Serum KL-6 levels fluctuated in a significant proportion of the patients but remained stable in the remaining patients. A wide range of variability of longitudinal KL-6 levels was associated with the presence of ILD, diffuse cutaneous SSc, positive anti-topoisomerase I antibodies, negative anticentromere antibodies, increased ILD extent on high-resolution computed tomography, extensive disease, low pulmonary function parameters, high KL-6 levels at baseline and immunomodulatory treatment. Extensive disease was consistently identified as an independent factor associated with variability in KL-6 levels in different models of multiple regression analysis. We failed to demonstrate correlations between trends for KL-6 level changes during the 6 months after SSc diagnosis and ILD progression over 2 years in patients with SSc-ILD. Serum KL-6 levels fluctuate in SSc patients with ILD, especially in those with extensive disease, but the clinical utility of a serial KL-6 level measurement remains uncertain.<\/jats:p>","DOI":"10.3390\/diagnostics11112007","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T23:50:28Z","timestamp":1635465028000},"page":"2007","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease"],"prefix":"10.3390","volume":"11","author":[{"given":"Yuichiro","family":"Shirai","sequence":"first","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo 113-8603, Japan"},{"name":"Scleroderma\/Myositis Center of Excellence, Nippon Medical School Hospital, Tokyo 113-8603, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Fukue","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo 113-8603, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo 113-8603, Japan"},{"name":"Scleroderma\/Myositis Center of Excellence, Nippon Medical School Hospital, Tokyo 113-8603, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5301\/jsrd.5000237","article-title":"Managing Systemic Sclerosis-Related Interstitial Lung Disease in the Modern Treatment Era","volume":"2","author":"Volkmann","year":"2017","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The Identification and Management of Interstitial Lung Disease in Systemic Sclerosis: Evidence-Based European Consensus Statements","volume":"2","author":"Maher","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/1744666X.2020.1777857","article-title":"Nintedanib for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"16","author":"Yamasaki","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in Systemic Sclerosis: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2397198320902551","article-title":"Recent Progress and Missing Gaps to Achieve Goal in the Care of Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"5","author":"Kuwana","year":"2020","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2021-eular.1067","article-title":"Progressive Interstitial Lung Disease in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the EUSTAR database","volume":"80","author":"Allanore","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3899\/jrheum.160339","article-title":"Elevated serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease","volume":"43","author":"Kuwana","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/rheumatology\/kev016","article-title":"Changes in Forced Vital Capacity over Time in Systemic Sclerosis: Application of Group-Based Trajectory Modelling","volume":"54","author":"Man","year":"2015","journal-title":"Rheumatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1378\/chest.13-2626","article-title":"Predictors of Mortality and Progression in Scleroderma-Associated Interstitial Lung Disease: A Systematic Review","volume":"146","author":"Winstone","year":"2014","journal-title":"Chest"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1902026","DOI":"10.1183\/13993003.02026-2019","article-title":"Predictors of Progression in Systemic Sclerosis Patients with Interstitial Lung Disease","volume":"55","author":"Distler","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.resinv.2012.02.001","article-title":"Utility of KL-6\/MUC1 in the Clinical Management of Interstitial Lung Diseases","volume":"50","author":"Ishikawa","year":"2012","journal-title":"Respir. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/rheumatology\/kez230","article-title":"Biomarkers in Systemic Sclerosis-Associated Interstitial Lung Disease: Review of the Literature","volume":"58","author":"Bonhomme","year":"2019","journal-title":"Rheumatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.chest.2020.03.037","article-title":"Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype","volume":"158","author":"Inoue","year":"2020","journal-title":"Chest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3899\/jrheum.170518","article-title":"KL-6 but Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-Related Interstitial Lung Disease","volume":"45","author":"Salazar","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/art.41020","article-title":"Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18","volume":"71","author":"Volkmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_17","first-page":"S138","article-title":"Follow-up of Serum KL-6 lung Fibrosis Biomarker Levels in 173 Patients with Systemic Sclerosis","volume":"32","author":"Minier","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative","volume":"65","author":"Khanna","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"ATS\/ERS Task Force. Standardisation of Spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An Official American Thoracic Society\/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial Lung Disease in Systemic Sclerosis: A Simple Staging System","volume":"177","author":"Goh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Corticosteroids and Intravenous Cyclophosphamide Followed by Oral Azathioprine for the Treatment of Pulmonary Fibrosis in Scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus Placebo in Scleroderma Lung Disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-Related Interstitial Lung Disease (SLS II): A Randomised Controlled, Double-Blind, Parallel Group Trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1272\/jnms.84.56","article-title":"Circulating Anti-Nuclear Antibodies in Systemic Sclerosis: Utility in Diagnosis and Disease Subsetting","volume":"84","author":"Kuwana","year":"2017","journal-title":"J. Nippon Med. Sch."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective Tissue Disease-Associated Interstitial Lung Diseases (CTD-ILD)\u2014Report from OMERACT CTD-ILD Working Group","volume":"42","author":"Khanna","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive Fibrosing Interstitial Lung Disease: Clinical Uncertainties, Consensus Recommendations, and Research Priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_29","unstructured":"Guilford, J.P. (1950). Fundamental Statistics in Psychology and Education, McGraw-Hill Series in Psychology, McGraw-Hill Book Company."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Young, D.S. (2017). Handbook of Regression Methods, CRC Press.","DOI":"10.1201\/9781315154701"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3109\/s10165-012-0756-0","article-title":"Marked Increase in Serum KL-6 and Surfactant Protein D Levels During the First 4 Weeks after Treatment Predicts Poor Prognosis in Patients with Active Interstitial Pneumonia Associated with Polymyositis\/Dermatomyositis","volume":"23","author":"Arai","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14397595.2018.1553488","article-title":"KL-6 is a Long-Term Disease-Activity Biomarker for Interstitial Lung Disease Associated with Polymyositis\/Dermatomyositis, but is Not a Short-Term Disease-Activity Biomarker","volume":"29","author":"Hanaoka","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/rheumatology\/key420","article-title":"Usefulness of Serum Krebs von den Lungen-6 for the Management of Myositis-Associated Interstitial Lung Disease","volume":"58","author":"Takanashi","year":"2019","journal-title":"Rheumatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e13542","DOI":"10.1097\/MD.0000000000013542","article-title":"Serial Measurements of KL-6 For Monitoring Activity and Recurrence of Interstitial Pneumonia with Anti-Aminoacyl-Trna Synthetase Antibody: A Retrospective Cohort Study","volume":"97","author":"Yamaguchi","year":"2018","journal-title":"Medicine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.resinv.2019.10.004","article-title":"Predictive Factors for the Recurrence of Anti-Aminoacyl-Trna Synthetase Antibody-Associated Interstitial Lung Disease","volume":"58","author":"Takei","year":"2020","journal-title":"Respir. Investig."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/11\/2007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:22:10Z","timestamp":1760167330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/11\/2007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["diagnostics11112007"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics11112007","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]}}}